- Report
- August 2023
- 150 Pages
North America
From €4586EUR$4,750USD£3,883GBP
- Report
- August 2023
- 80 Pages
Middle East, Africa
From €4586EUR$4,750USD£3,883GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4586EUR$4,750USD£3,883GBP
- Report
- August 2023
- 70 Pages
Latin America
From €4586EUR$4,750USD£3,883GBP
- Report
- August 2023
- 80 Pages
Europe
From €4586EUR$4,750USD£3,883GBP
- Report
- August 2023
- 70 Pages
North America
From €4586EUR$4,750USD£3,883GBP
- Report
- August 2023
- 70 Pages
Asia Pacific
From €4586EUR$4,750USD£3,883GBP
- Report
- August 2023
- 80 Pages
Africa
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2021
- 500 Pages
United States
From €1970EUR$2,040USD£1,668GBP
€2317EUR$2,400USD£1,962GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €2954EUR$3,060USD£2,502GBP
€3476EUR$3,600USD£2,943GBP
- Report
- May 2020
- 121 Pages
Global
From €4200EUR$4,350USD£3,556GBP
- Report
- February 2024
- 70 Pages
Iran
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 70 Pages
India
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 70 Pages
Germany
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 70 Pages
Italy
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 70 Pages
Oman
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4586EUR$4,750USD£3,883GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4586EUR$4,750USD£3,883GBP
![Loading Indicator](//www.researchandmarkets.com/images/loading.gif)
Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more